Skip to main content
OCS
NASDAQ Life Sciences

FDA Clears IND, Opening Acute MS Relapse Path for Privosegtor

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$7.64
Mkt Cap
$471.633M
52W Low
$6.78
52W High
$34.475
52W Position info
13% above low
Off High info
78% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

OCS is trading near its 52-week low of $6.78 (13% above the low).

Summary

The FDA cleared the IND for Privosegtor in acute MS relapses, letting Oculis cross-reference data from its existing ophthalmology IND and run a trial with a primary endpoint as early as three months at the same 3mg/kg daily dose for five days used in PIONEER-1. The expansion rests on the completed Phase 2 ACUITY study, where the drug improved visual function, preserved retinal ganglion cell layer integrity, and cut NfL and GFAP blood levels. Oculis frames this as a large unmet need: roughly 2.8 million people have MS worldwide and an estimated 170,000 relapses occur annually in the U.S., with no approved neuroprotective therapy for acute attacks. It is a pipeline-expansion win for a small-cap name, not a revenue event — Privosegtor remains investigational and the registrational PIONEER program in optic neuropathies is still the nearer-term value driver. The company hosts an R&D Day on December 8, 2026, to detail the pivotal plan for acute MS relapses and update on PIONEER.

At the time of this announcement, OCS was trading at $7.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471.6M. The 52-week trading range was $6.78 to $34.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

OCS - Latest Insights

OCS
Nov 03, 2026, 4:19 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $7.64 info
Change: -$0.253 (-3%) info
Market Cap: $471.633M info
OCS
Nov 03, 2026, 4:15 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $7.64 info
Change: -$0.253 (-3%) info
Market Cap: $471.633M info
OCS
Aug 10, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $12.98
Real-time Price: $7.64 info
Change: -$5.34 (-41%) info
Market Cap: $471.633M info
OCS
Aug 10, 2026, 3:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $12.68
Real-time Price: $7.64 info
Change: -$5.04 (-40%) info
Market Cap: $471.633M info
OCS
Aug 06, 2026, 4:32 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $12.38
Real-time Price: $7.64 info
Change: -$4.74 (-38%) info
Market Cap: $471.633M info